What's in Nanjing Yoko Biomedical Co., Ltd.'s pipeline?

Nanjing Yoko Biomedical Co., Ltd. has 5 drugs in our index: 0 marketed, 0 filed, 4 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Nanjing Yoko Biomedical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Agendia, Asan Medical Center, Bayer, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Children's Cancer Group, China.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nanjing-yoko-biomedical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Nanjing Yoko Biomedical Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nanjing Yoko Biomedical Co., Ltd. pipeline: 0 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 4 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
G-CHOP	G-CHOP	phase 3	Chemotherapy combination regimen		Oncology
Control group: Oxiracetam Injection	Control group: Oxiracetam Injection	phase 3	Nootropic agent		Neurology
Ncardipine Hydrochloride Injection	Ncardipine Hydrochloride Injection	phase 3	Dihydropyridine calcium channel blocker	L-type voltage-gated calcium channel	Cardiovascular
Test group: L-oxiracetam Injection	Test group: L-oxiracetam Injection	phase 3	Nootropic agent / Pyrrolidone derivative		Neurology / Cognitive disorders

Therapeutic area mix

Cardiovascular · 1
Neurology · 1
Neurology / Cognitive disorders · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Agendia · 1 shared drug class
Asan Medical Center · 1 shared drug class
Bayer · 1 shared drug class
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 shared drug class
Children's Cancer Group, China · 1 shared drug class
China Breast Cancer Clinical Study Group · 1 shared drug class
Fujian Medical University · 1 shared drug class
AGO Study Group · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nanjing Yoko Biomedical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Nanjing Yoko Biomedical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nanjing-yoko-biomedical-co-ltd. Accessed 2026-05-17.